In these cases, an appropriate genotype–phenotype correlation analysis is necessary so as not to attribute treatment failure to patients who are not going to develop kidney damage due to FD, such as patients with late-onset cardiac phenotypes or benign GLA gene variants carriers [21]. This evidence concerns the gene GLA and Nephropathy.